Prosecution Insights
Last updated: April 19, 2026
Application No. 18/546,609

PROCESS FOR PREPARING AN E-SELECTIN INHIBITOR INTERMEDIATE

Non-Final OA §112
Filed
Aug 16, 2023
Examiner
KRISHNAN, GANAPATHY
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Glycomimetics Inc.
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
3y 4m
To Grant
53%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allow Rate
566 granted / 1087 resolved
-7.9% vs TC avg
Minimal +0% lift
Without
With
+0.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
63 currently pending
Career history
1150
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1087 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-72 are pending in the application. Preliminary amendment filed 16 August 2023. Priority This application is a 371 of PCT/US2022/016696 filed 02/17/2022, which claims the benefit of 63150940 filed 02/18/2021. Claim Objections Claim 18 is objected to because of the following informalities: In claim 18, Formula 1 and 2 have the TBS protecting group. The protecting group in formula 3 is TBDMS. Is TBS also used as a notation for t-butyldimethylsilyl? Correction is needed for consistency. This also applies to claim 54. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-17, and 35-53 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is drawn to a process for making compound of formula 16. However, only two steps (a) and (b) are recited as alternatives. These two steps are seen only as part of the process steps. Additional steps are seen to be needed to arrive at the compound of formula 16. This renders the claim indefinite. This also applies to claim 35 since claim 35 recites only the epoxide ring opening as a step in the process for making formula 16. Claim 1 recites at least one step chosen from and recites parts (a) and (b). If the step in part (b) is chosen does it mean that the epoxide ring opening as in part (a) need not be chosen since the claim recites at least one step chosen from? This also applies to claims 18 and 35. Claims 2 is drawn to the process of claim 1 wherein both steps (a) and (b) are used. Additional steps are needed to get to formula 16 which are not recited. Claims 3-17, 37, and 42-46, which depend from a rejected base claim that is unclear/indefinite are also rendered unclear/indefinite and are rejected for the same reasons. All claims which depend from an indefinite claim are also indefinite. Ex parte Cordova, 10 U.S.P.Q. 2d 1949, 1952 (P.T.O. Bd. App. 1989). Conclusion 1. Claims 1-17, and 35-53 are rejected. 2. Claims 18-34, and 54-72 are allowable. Since claims18, 20-22, and 25-30 are found to be allowable, claims 54-55, 60, and 66-72 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Any inquiry concerning this communication or earlier communications from the examiner should be directed to GANAPATHY KRISHNAN whose telephone number is (571)272-0654. The examiner can normally be reached M-F 8.30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GANAPATHY KRISHNAN/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Aug 16, 2023
Application Filed
Dec 10, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600742
MARKERS, CONJUGATES, COMPOSITIONS AND METHODS FOR HYPOXIA IMAGING, MAPPING, AND THERAPY
2y 5m to grant Granted Apr 14, 2026
Patent 12594296
METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK
2y 5m to grant Granted Apr 07, 2026
Patent 12589108
Injectable bifunctional hydrogel with antibacterial activity as well as the preparative method and the use thereof
2y 5m to grant Granted Mar 31, 2026
Patent 12590306
PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS
2y 5m to grant Granted Mar 31, 2026
Patent 12582148
Compositions and Methods for Improving Quality of Life in Patients with Autism Spectrum Disorder
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
53%
With Interview (+0.5%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 1087 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month